- Academic Editor
-
-
-
Background: The impact of the methylenetetrahydrofolate
reductase (MTHFR) C677T mutation on the relationship between plasma
homocysteine (Hcy) levels and stroke has been extensively studied and documented
in previous study. However, it remains unclear whether the MTHFR C677T
mutation can affect the response to Hcy lowering treatment in stroke patients
with hyperhomocysteinemia (HHcy). Understanding the impact of genetic factors on
treatment response can help optimize personalized treatment strategies for stroke
patients with HHcy. We aimed to investigate the potential association between the
MTHFR C677T gene polymorphisms and the effectiveness of Hcy lowering
treatment using vitamin therapy in stroke patients with HHcy.
Methods: The MTHFR C677T genotype polymorphisms were
identified using polymerase chain reaction-restriction fragment length
polymorphism, and the distribution of three genotypes in the MTHFR C677T
gene locus was compared. The treatment effects of Hcy lowering agents were
compared among patients with different genotypes.
Results: Among the 320 stroke
patients enrolled in the study, 258 (80.6%) were diagnosed with HHcy. Of these,
162 patients (Effective Group) responded well to the clinical Hcy lowering
treatment, while 96 patients (Invalid Group) failed to achieve sufficient
response even after taking combination supplements of folic acid, Vitamin B6, and
methylcobalamin for one month. Significant differences were observed in terms of
age (p